Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Medical Genetics

What is the Lyso-Gb3 Test for Fabry Disease?

At a Glance

The Lyso-Gb3 blood test measures a toxic fatty substance that builds up in patients with Fabry disease. Doctors use this test every 6-12 months to confirm a diagnosis, track disease severity, and ensure treatments are effectively clearing the buildup to protect vital organs.

In this answer

4 sections

01

What is Lyso-Gb3?

02

Role 1: Confirming Diagnosis and Severity

03

Role 2: Tracking Your Treatment

04

What to Expect and How Often to Test

The Lyso-Gb3 test is a blood test used to measure the amount of a specific toxic fatty substance—globotriaosylsphingosine, or Lyso-Gb3—in your bloodstream. In people with Fabry disease, a missing or faulty enzyme causes this fatty substance to build up instead of being broken down [1]. Doctors rely on the Lyso-Gb3 test for two main reasons: to help confirm a Fabry disease diagnosis and understand its severity, and to track whether treatments are successfully clearing the buildup from your body over time [2][3].

What is Lyso-Gb3?

In a body without Fabry disease, an enzyme called alpha-Gal A acts like a cellular recycling center, breaking down specific fats. When this enzyme isn’t working correctly, a toxic fatty substance called Lyso-Gb3 accumulates in your cells [4]. Over time, this buildup can cause damage to vital organs, particularly the kidneys, heart, and nervous system [5][6].

Role 1: Confirming Diagnosis and Severity

When you are first being evaluated for Fabry disease, checking your Lyso-Gb3 levels helps doctors piece together the puzzle of your diagnosis.

  • Disease Severity: Higher levels of Lyso-Gb3 generally correlate with a more severe form of the disease, often seen in the “classic” type of Fabry disease [5][7]. Lower, but still elevated, levels are often seen in late-onset types [8].
  • The Female Exception: While this test is highly accurate for men, it is less sensitive for women [9]. Because women have two X chromosomes, a healthy gene can sometimes clear enough of the substance from the blood to mask the buildup. Therefore, a woman with Fabry disease can sometimes have completely normal Lyso-Gb3 levels [10]. Because of this exception, definitive diagnosis in women often requires direct genetic (DNA) testing to look for the Fabry gene mutation.

Role 2: Tracking Your Treatment

Once you are diagnosed and begin treatment—such as Enzyme Replacement Therapy (ERT, an infused enzyme) or chaperone therapy (an oral medication that helps your existing enzymes work better)—your doctor will use the Lyso-Gb3 test as a primary tracking metric to see if the medication is working [11][12].

  • Signs of Success: If your treatment is effective, your Lyso-Gb3 levels should significantly drop and then remain stable at a lower level [13].
  • Warning Signs: If your numbers do not go down after starting treatment, or if they drop but later start rising again, it is a crucial warning sign [3]. In patients on ERT, rising numbers can indicate that the immune system has developed neutralizing antibodies—meaning your body is fighting off the infused enzyme and stopping it from doing its job [14][15].

What to Expect and How Often to Test

Because tracking the trend of your Lyso-Gb3 levels is so vital to protecting your organs, standard guidelines recommend having this blood test drawn every 6 to 12 months [16].

  • The Testing Process: This test is usually a standard blood draw from a vein, though some specialized Fabry clinics use a simple “Dried Blood Spot” (DBS) finger-prick card. You typically do not need to fast beforehand, but always verify with your lab or doctor’s office.
  • Understanding Your Numbers: Normal reference ranges can vary widely depending on the specific lab analyzing the sample. Instead of focusing purely on the raw number, ask your doctor what your specific baseline target should be.

Watching these numbers over time tells your care team whether they need to check for neutralizing antibodies or switch you to a different type of therapy to keep the disease in check.

Common questions in this guide

What is Lyso-Gb3?
Lyso-Gb3 is a toxic fatty substance that builds up in the cells of people with Fabry disease. This accumulation happens because patients lack a properly functioning alpha-Gal A enzyme needed to break down these specific fats.
Can women with Fabry disease have normal Lyso-Gb3 levels?
Yes, women with Fabry disease can sometimes have normal Lyso-Gb3 blood levels. Because women have two X chromosomes, a healthy gene can sometimes clear enough of the substance to mask the buildup, often requiring DNA testing for a definitive diagnosis.
What does it mean if my Lyso-Gb3 levels go up while on treatment?
If your levels rise while on Enzyme Replacement Therapy (ERT), it may mean your immune system has developed neutralizing antibodies. This indicates your body is fighting off the infused enzyme, and you may need to discuss alternative treatment plans with your doctor.
How often should I get a Lyso-Gb3 test?
Standard medical guidelines recommend having your Lyso-Gb3 levels checked every 6 to 12 months. This regular monitoring helps your care team accurately track if your treatment is working or if adjustments need to be made.
Do I need to fast before a Lyso-Gb3 blood test?
You typically do not need to fast before a Lyso-Gb3 blood draw, which can be done through a standard vein draw or a finger-prick dried blood spot test. However, you should always verify specific instructions with your testing lab or doctor beforehand.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my current baseline Lyso-Gb3 number, and what target number are we aiming for with my treatment?
  2. 2.Should I make sure to use the exact same lab facility every time to ensure my trend lines are accurate when comparing results?
  3. 3.If my Lyso-Gb3 levels start to rise while on my current Enzyme Replacement Therapy, what is our 'Plan B' for treatment?
  4. 4.Since I am female and my Lyso-Gb3 levels are normal, what other tests or genetic screening will we use to monitor my disease progression?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Can Female Carriers of Fabry Disease Have Severe Symptoms?How Is Enzyme Replacement Therapy Administered for Fabry?How Is Fabry Disease Inherited From a Father?How Is Fabry Disease Inherited From a Mother?How Often Should I Get a Cardiac MRI for Fabry Disease?How Do You Manage Heat Intolerance in Fabry Disease?How to Transition a Child With Fabry to Adult CareHow to Treat Fabry Disease Nerve Pain in Hands & FeetCan Your Body Stop Responding to Fabry Disease ERT?What Are the Common Misdiagnoses for Fabry Disease?What Does an Amenable Mutation Mean in Fabry Disease?Fabry Disease Prognosis: What Is the Life Expectancy?What Specialists Treat Fabry Disease? Care Team GuideWhy Do Women Need Genetic Testing for Fabry Disease?

References

References (16)
  1. 1

    A comprehensive testing algorithm for the diagnosis of Fabry disease in males and females.

    Stiles AR, Zhang H, Dai J, et al.

    Molecular genetics and metabolism 2020; (130(3)):209-214 doi:10.1016/j.ymgme.2020.04.006.

    PMID: 32418857
  2. 2

    Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis.

    Maruyama H, Miyata K, Mikame M, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2019; (21(1)):44-52 doi:10.1038/gim.2018.31.

    PMID: 29543226
  3. 3

    Fabry Disease Nephropathy: Compendium of "in vitro" and "in vivo" Renal Effects of Globotriaosylsphingosine.

    Jaurretche SPA, Del Rosal MV, Brajkovic ML, et al.

    Kidney & blood pressure research 2025; (50(1)):811-819 doi:10.1159/000547144.

    PMID: 41234045
  4. 4

    RIPK3 Contributes to Lyso-Gb3-Induced Podocyte Death.

    Kim SY, Park S, Lee SW, et al.

    Cells 2021; (10(2)) doi:10.3390/cells10020245.

    PMID: 33513913
  5. 5

    Biomarkers associated with clinical manifestations in Fabry disease patients with a late-onset cardiac variant mutation.

    Auray-Blais C, Lavoie P, Boutin M, et al.

    Clinica chimica acta; international journal of clinical chemistry 2017; (466()):185-193 doi:10.1016/j.cca.2017.01.018.

    PMID: 28108302
  6. 6

    Epithelial-Mesenchymal Transition in Kidney Tubular Epithelial Cells Induced by Globotriaosylsphingosine and Globotriaosylceramide.

    Jeon YJ, Jung N, Park JW, et al.

    PloS one 2015; (10(8)):e0136442 doi:10.1371/journal.pone.0136442.

    PMID: 26291612
  7. 7

    Late-onset and classic phenotypes of Fabry disease in males with the GLA-Thr410Ala mutation.

    Valtola K, Hedman M, Kantola I, et al.

    Open heart 2023; (10(1)) doi:10.1136/openhrt-2023-002251.

    PMID: 36927868
  8. 8

    A new mutation found in newborn screening for Fabry disease evaluated by plasma globotriaosylsphingosine levels.

    Chinen Y, Nakamura S, Yoshida T, et al.

    Human genome variation 2017; (4()):17002 doi:10.1038/hgv.2017.2.

    PMID: 28224042
  9. 9

    The use and performance of lyso-Gb3 for the diagnosis and monitoring of Fabry disease: A systematic literature review.

    Ramaswami U, West ML, Tylee K, et al.

    Molecular genetics and metabolism 2025; (145(2)):109110 doi:10.1016/j.ymgme.2025.109110.

    PMID: 40328031
  10. 10

    Diagnostic strategy for females suspected of Fabry disease.

    Balendran S, Oliva P, Sansen S, et al.

    Clinical genetics 2020; (97(4)):655-660 doi:10.1111/cge.13694.

    PMID: 31860127
  11. 11

    Monitoring globotriaosylsphingosine in a Korean male patient with Fabry disease.

    Jang H, Joo KW, Han SS

    Kidney research and clinical practice 2019; (38(2)):250-252 doi:10.23876/j.krcp.18.0156.

    PMID: 31016956
  12. 12

    Late-onset renal variant Fabry disease with R112H mutation and mild increase in plasma globotriaosylsphingosine: a case report.

    Tanaka K, Sugiyama H, Morinaga H, et al.

    Frontiers in medicine 2024; (11()):1383309 doi:10.3389/fmed.2024.1383309.

    PMID: 38903807
  13. 13

    A simple method for quantification of plasma globotriaosylsphingosine: Utility for Fabry disease.

    Talbot A, Nicholls K, Fletcher JM, Fuller M

    Molecular genetics and metabolism 2017; (122(1-2)):121-125 doi:10.1016/j.ymgme.2017.08.004.

    PMID: 28847675
  14. 14

    Anti-drug antibody formation in Japanese Fabry patients following enzyme replacement therapy.

    Tsukimura T, Tayama Y, Shiga T, et al.

    Molecular genetics and metabolism reports 2020; (25()):100650 doi:10.1016/j.ymgmr.2020.100650.

    PMID: 33072516
  15. 15

    Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy.

    Sakuraba H, Togawa T, Tsukimura T, Kato H

    Clinical and experimental nephrology 2018; (22(4)):843-849 doi:10.1007/s10157-017-1525-3.

    PMID: 29288396
  16. 16

    New insights in efficacy of different ERT dosages in Fabry disease: Switch and switch-back studies data following agalsidase beta shortage. Update of systematic review.

    Riccio E, Garofalo C, Capuano I, et al.

    Genetics in medicine open 2023; (1(1)):100805 doi:10.1016/j.gimo.2023.100805.

    PMID: 39669233

This page explains the Lyso-Gb3 test for Fabry disease for educational purposes only. Always consult your doctor or metabolic specialist to interpret your specific lab baseline, target numbers, and treatment plan.

Get notified when new evidence is published on Fabry disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.